Deletion of sterol O-acyltransferase 2 (SOAT2) function in mice deficient in lysosomal acid lipase (LAL) dramatically reduces esterified cholesterol sequestration in the small intestine and liver

Adam M. Lopez, Kenneth S. Posey, Stephen D. Turley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sterol O-acyltransferase 2 (SOAT2), also known as ACAT2, is the major cholesterol esterifying enzyme in the liver and small intestine (SI). Esterified cholesterol (EC) carried in certain classes of plasma lipoproteins is hydrolyzed by lysosomal acid lipase (LAL) when they are cleared from the circulation. Loss-of-function mutations in LIPA, the gene that encodes LAL, result in Wolman disease (WD) or cholesteryl ester storage disease (CESD). Hepatomegaly and a massive increase in tissue EC levels are hallmark features of both disorders. While these conditions can be corrected with enzyme replacement therapy, the question arose as to what effect the loss of SOAT2 function might have on tissue EC sequestration in LAL-deficient mice. When weaned at 21 days, Lal-/-:Soat2+/+ mice had a whole liver cholesterol content (mg/organ) of 24.7 mg vs 1.9 mg in Lal+/+:Soat2+/+ littermates, with almost all the excess sterol being esterified. Over the next 31 days, liver cholesterol content in the Lal-/-:Soat2+/+ mice increased to 145 ± 2 mg but to only 29 ± 2 mg in their Lal-/-:Soat2-/- littermates. The level of EC accumulation in the SI of the Lal-/-:Soat2-/- mice was also much less than in their Lal-/-:Soat2+/+ littermates. In addition, there was a >70% reduction in plasma transaminase activities in the Lal-/-:Soat2-/- mice. These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.

Original languageEnglish (US)
Pages (from-to)162-166
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume454
Issue number1
DOIs
StatePublished - Nov 7 2014

Fingerprint

Sterol Esterase
Liver
Small Intestine
Cholesterol
Cholesterol Ester Storage Disease
Cholesterol Esters
Wolman Disease
Sterol O-Acyltransferase
Tissue
Enzyme Replacement Therapy
Plasmas
Hepatomegaly
Sterols
Transaminases
Lipoproteins
sterol O-acyltransferase 2
Thermodynamic properties
Genes
Mutation
Enzymes

Keywords

  • Cholesterol esterification
  • Cholesteryl ester storage disease
  • Hepatomegaly
  • Liver transaminase activity
  • Triacylglycerol
  • Unesterified cholesterol

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

@article{87f9a90a444342069256fff6580716a1,
title = "Deletion of sterol O-acyltransferase 2 (SOAT2) function in mice deficient in lysosomal acid lipase (LAL) dramatically reduces esterified cholesterol sequestration in the small intestine and liver",
abstract = "Sterol O-acyltransferase 2 (SOAT2), also known as ACAT2, is the major cholesterol esterifying enzyme in the liver and small intestine (SI). Esterified cholesterol (EC) carried in certain classes of plasma lipoproteins is hydrolyzed by lysosomal acid lipase (LAL) when they are cleared from the circulation. Loss-of-function mutations in LIPA, the gene that encodes LAL, result in Wolman disease (WD) or cholesteryl ester storage disease (CESD). Hepatomegaly and a massive increase in tissue EC levels are hallmark features of both disorders. While these conditions can be corrected with enzyme replacement therapy, the question arose as to what effect the loss of SOAT2 function might have on tissue EC sequestration in LAL-deficient mice. When weaned at 21 days, Lal-/-:Soat2+/+ mice had a whole liver cholesterol content (mg/organ) of 24.7 mg vs 1.9 mg in Lal+/+:Soat2+/+ littermates, with almost all the excess sterol being esterified. Over the next 31 days, liver cholesterol content in the Lal-/-:Soat2+/+ mice increased to 145 ± 2 mg but to only 29 ± 2 mg in their Lal-/-:Soat2-/- littermates. The level of EC accumulation in the SI of the Lal-/-:Soat2-/- mice was also much less than in their Lal-/-:Soat2+/+ littermates. In addition, there was a >70{\%} reduction in plasma transaminase activities in the Lal-/-:Soat2-/- mice. These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.",
keywords = "Cholesterol esterification, Cholesteryl ester storage disease, Hepatomegaly, Liver transaminase activity, Triacylglycerol, Unesterified cholesterol",
author = "Lopez, {Adam M.} and Posey, {Kenneth S.} and Turley, {Stephen D.}",
year = "2014",
month = "11",
day = "7",
doi = "10.1016/j.bbrc.2014.10.063",
language = "English (US)",
volume = "454",
pages = "162--166",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Deletion of sterol O-acyltransferase 2 (SOAT2) function in mice deficient in lysosomal acid lipase (LAL) dramatically reduces esterified cholesterol sequestration in the small intestine and liver

AU - Lopez, Adam M.

AU - Posey, Kenneth S.

AU - Turley, Stephen D.

PY - 2014/11/7

Y1 - 2014/11/7

N2 - Sterol O-acyltransferase 2 (SOAT2), also known as ACAT2, is the major cholesterol esterifying enzyme in the liver and small intestine (SI). Esterified cholesterol (EC) carried in certain classes of plasma lipoproteins is hydrolyzed by lysosomal acid lipase (LAL) when they are cleared from the circulation. Loss-of-function mutations in LIPA, the gene that encodes LAL, result in Wolman disease (WD) or cholesteryl ester storage disease (CESD). Hepatomegaly and a massive increase in tissue EC levels are hallmark features of both disorders. While these conditions can be corrected with enzyme replacement therapy, the question arose as to what effect the loss of SOAT2 function might have on tissue EC sequestration in LAL-deficient mice. When weaned at 21 days, Lal-/-:Soat2+/+ mice had a whole liver cholesterol content (mg/organ) of 24.7 mg vs 1.9 mg in Lal+/+:Soat2+/+ littermates, with almost all the excess sterol being esterified. Over the next 31 days, liver cholesterol content in the Lal-/-:Soat2+/+ mice increased to 145 ± 2 mg but to only 29 ± 2 mg in their Lal-/-:Soat2-/- littermates. The level of EC accumulation in the SI of the Lal-/-:Soat2-/- mice was also much less than in their Lal-/-:Soat2+/+ littermates. In addition, there was a >70% reduction in plasma transaminase activities in the Lal-/-:Soat2-/- mice. These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.

AB - Sterol O-acyltransferase 2 (SOAT2), also known as ACAT2, is the major cholesterol esterifying enzyme in the liver and small intestine (SI). Esterified cholesterol (EC) carried in certain classes of plasma lipoproteins is hydrolyzed by lysosomal acid lipase (LAL) when they are cleared from the circulation. Loss-of-function mutations in LIPA, the gene that encodes LAL, result in Wolman disease (WD) or cholesteryl ester storage disease (CESD). Hepatomegaly and a massive increase in tissue EC levels are hallmark features of both disorders. While these conditions can be corrected with enzyme replacement therapy, the question arose as to what effect the loss of SOAT2 function might have on tissue EC sequestration in LAL-deficient mice. When weaned at 21 days, Lal-/-:Soat2+/+ mice had a whole liver cholesterol content (mg/organ) of 24.7 mg vs 1.9 mg in Lal+/+:Soat2+/+ littermates, with almost all the excess sterol being esterified. Over the next 31 days, liver cholesterol content in the Lal-/-:Soat2+/+ mice increased to 145 ± 2 mg but to only 29 ± 2 mg in their Lal-/-:Soat2-/- littermates. The level of EC accumulation in the SI of the Lal-/-:Soat2-/- mice was also much less than in their Lal-/-:Soat2+/+ littermates. In addition, there was a >70% reduction in plasma transaminase activities in the Lal-/-:Soat2-/- mice. These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.

KW - Cholesterol esterification

KW - Cholesteryl ester storage disease

KW - Hepatomegaly

KW - Liver transaminase activity

KW - Triacylglycerol

KW - Unesterified cholesterol

UR - http://www.scopus.com/inward/record.url?scp=84910142926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910142926&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2014.10.063

DO - 10.1016/j.bbrc.2014.10.063

M3 - Article

C2 - 25450374

AN - SCOPUS:84910142926

VL - 454

SP - 162

EP - 166

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -